Dermatomyositis is a rare muscular disorder characterized by a concurrent skin rash, impacting individuals of all ages, including both adults and children. In adults, it typically manifests between the late 40s and early 60s, while in children, it tends to occur between 5 and 15 years of age. Dermatomyositis is more commonly observed in females than males.

The predominant symptom associated with dermatomyositis is the development of a purple or dark red rash, which can emerge anywhere on the skin. However, it is most frequently observed on the eyelids and in regions where muscle covers a joint, such as the elbows, knees, knuckles, and toes. In addition to the skin manifestations, individuals may experience muscle discomfort, weakness, muscle atrophy (a decrease in muscle size), and impaired muscle function. The severity and frequency of these symptoms can differ among individuals.

While the precise cause of dermatomyositis remains elusive, it shares similarities with other autoimmune conditions where the immune system mistakenly targets the body’s own tissues. Ongoing research aims to uncover additional factors that could contribute to its onset. Some potential factors being investigated include infections, a higher likelihood of underlying skin cancer (especially in the elderly), and genetic predisposition.

Dermatomyositis currently lacks a cure. The primary objective of treatment is to manage both the skin condition and muscle strength and function. Treatment alternatives encompass antimalarial drugs, corticosteroids for inflammation reduction, immunosuppressive medications, intravenous immunoglobulins (IVIG) to temper the immune response, pain relief medications, and steroid-sparing agents. Additionally, crucial aspects of dermatomyositis management include physical therapy, speech therapy, and dietary guidance.

The typical approach to treating dermatomyositis primarily involves oral corticosteroids aimed at slowing the disease’s progression. In some cases, immunosuppressive medications are used alongside corticosteroids. However, it’s important to note that these medications often come with significant side effects, and the response to conventional therapy may fall short of expectations.

For individuals with dermatomyositis who do not respond adequately to or cannot tolerate conventional therapy, intravenous immunoglobulin (IVIG) serves as an effective supplementary treatment. Clinical trial summaries indicate an overall response rate of approximately 80% after around 2 months, with the most substantial response observed at the 4-month mark. In many cases, ongoing IVIG therapy is necessary in addition to conventional treatments, administered at lower doses that are better tolerated by the patient.

IVIG is typically prescribed to be administered monthly at a dosage of 1-2 grams per kilogram of body weight, delivered over a 5-day course. Typically, the effects of IVIG can be sustained for up to a month following each administration. The infusion of IVIG takes place through a vein, typically spanning a duration of 4 to 6 hours.

Skin reactions to IVIG are infrequent, with the most prevalent reported rash being a blistering form of eczema. This reaction typically emerges approximately 8 to 10 days following exposure to IVIG. Initially, it manifests as small, itchy blisters on the palms and/or soles before spreading to other areas of the body. Individuals affected by this reaction may experience generalized redness and itching. Switching to a different type of IVIG may help alleviate the reaction.

In most cases, the skin lesions resolve within 1 to 4 weeks. Symptoms can be managed and recovery expedited through the use of steroids.

Reference:
Vecchietti, G., et al. (2006). Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol, 142(2), 213-7.

Pemphigus comprises a collection of uncommon autoimmune disorders characterized by the formation of blisters on the skin and mucous membranes, including those found in the mouth, nose, throat, eyes, and genital areas.

There are multiple types of pemphigus, with the specific subtype determined by the skin layer where blisters develop and their location on the body. The two primary types are:

1. Pemphigus Vulgaris: This is the most prevalent subtype of pemphigus, both in the United States and globally. It is characterized by the presence of blisters and erosions on the skin and mucous membranes, most commonly within the oral cavity.

2. Pemphigus Foliaceus: In this variant, blistering lesions typically initiate on the face and scalp before spreading to the chest and other body areas. These sores are superficial, often itchy, and generally not associated with pain.

Pemphigus is an autoimmune condition characterized by blister formation, signifying that the immune system targets its own cells in the top layer of the skin (the epidermis) and the mucous membranes. The exact cause of this disease remains unclear, although there seems to be a genetic predisposition in some individuals. Environmental factors may serve as triggers for pemphigus in individuals who are genetically predisposed to the disease. In rare instances, specific medications may act as triggers; typically, the disease resolves when the causative medication is discontinued.

The main objective of treatment is to reduce blister formation, prevent infections, and facilitate the healing process for blisters and erosions in pemphigus patients. The treatment approach typically involves the use of one or more medications. High doses of oral corticosteroids serve as the cornerstone of medical therapy to manage the condition effectively. Immunosuppressive medications are frequently introduced to the treatment plan to minimize the reliance on steroids. In severe instances of pemphigus, intravenous immunoglobulin (IVIG) therapy may be necessary to lower the antibody levels in the bloodstream.

The treatment approach for pemphigus and pemphigoid typically involves the administration of one or more medications. The primary component of current treatment protocols revolves around the use of high-dose oral corticosteroids, such as prednisone or prednisolone. Nevertheless, the prolonged or high-dosage utilization of corticosteroids carries the potential for severe side effects, including the development of type 2 diabetes, osteoporosis, an elevated susceptibility to infections, fluid retention, cataracts, and facial and upper back swelling.

To minimize the reliance on corticosteroids, immunosuppressive agents are often introduced as supplementary components of the treatment plan. It is important to note that these medications may also entail substantial side effects, such as an increased risk of infections, anemia, liver inflammation, nausea, vomiting, or allergic reactions.

IVIG proves to be an effective therapeutic option for individuals afflicted with pemphigus. Its mechanism of action appears to involve the rapid and specific reduction of pemphigus antibodies in the bloodstream.[1] The extent of this antibody decrease can vary from patient to patient, with some experiencing a marked reduction while others see a more modest decline. IVIG treatment displays a remarkable selectivity in targeting pemphigus antibodies.

The mode of action of IVIG closely resembles that of plasmapheresis. Both methods swiftly eliminate circulating pemphigus antibodies from the bloodstream at approximately equal rates. However, IVIG boasts significant advantages over plasmapheresis in that it selectively removes pemphigus antibodies. In contrast, plasmapheresis, as conventionally performed, eliminates all circulating immunoglobulins, indiscriminately removing the beneficial ones alongside the harmful ones. Moreover, IVIG is generally considered safer[1], causing no harm to red blood cells and inflicting less damage to venous access.

Reference:

1. Engineer, L, Bhol, KC, Ahmed, AR: Analysis of current data on the use of intravenous immunoglobulin in the management of pemphigus vulgaris. J Am Acad Dermatol 43:1049-1057, 2000.

Typically, the IVIG dosage consists of 2 grams of IVIG per kilogram of body weight per treatment cycle, administered over a span of 5 days. These cycles are usually repeated every 2 to 4 weeks and may continue for several months.

There is a widespread consensus regarding the appropriate use of IVIG for managing pemphigus cases that do not respond to traditional therapies or in instances where serious complications arise during standard treatment. Other suggested indications encompass scenarios such as the inability to taper off steroids without a disease flare-up, the presence of absolute or relative contraindications to systemic steroid use, and the persistence of disease progression despite the application of suitable and safe conventional therapies [1]. It is crucial to note that the decision to employ IVIG in pemphigus treatment can be significantly influenced by the policies of Medicare or the patient’s insurance plan responsible for covering the treatment costs. These indications may vary depending on the specific plan, and Medicare’s guidelines may differ from region to region within the United States.

Reference:

1. Engineer, L, Bhol, KC, Ahmed, AR: Comprehensive Analysis of Intravenous Immunoglobulin Usage in the Management of Pemphigus Vulgaris. Journal of the American Academy of Dermatology, 43(6), 1049-1057, 2000.

It’s important to understand that the information provided on this website should not be considered a replacement for expert medical advice, diagnosis, or treatment. Medrx Infusion neither endorses nor recommends any particular tests, products, procedures, or other details mentioned on this website. For more information, please refer to our Terms of Use section.